Usana Health Sciences Inc (USNA) Financial Statements
Industry: Medicinal Chemicals & Botanical Products
In fiscal 2025, Usana Health Sciences reported revenue of $925.3M, up 8.3% from $854.5M the year before. Net income was $10.8M (a 1.2% net margin), or $0.58 per diluted share. Gross margin was 78.3% and operating margin was 4.0%. Operating activities generated $22.3M of cash, leaving $8.5M of free cash flow. At fiscal year end, Usana Health Sciences held $742.9M in total assets against $156.6M in total liabilities, including $158.4M of cash and equivalents.
Open the full interactive Usana Health Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
Usana Health Sciences Key Stats
| Share Price | $15.46 |
|---|---|
| Market Cap | $285.8M |
| P/E Ratio | 26.7 |
| Revenue YoY Growth | +8.3% |
| 52-Week Range | $12.86 – $23.24 |
| Shares Outstanding | 18.5 million (basic, 2026 Q2) |
Usana Health Sciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.13B | $1.19B | $998.6M | $921.0M | $854.5M | $925.3M |
| Cost of Goods Sold | $209.1M | $217.9M | $193.9M | $176.7M | $161.2M | $200.9M |
| Gross Profit | $925.5M | $968.6M | $804.7M | $744.3M | $693.3M | $724.4M |
| Operating Income | $176.5M | $170.2M | $107.6M | $93.1M | $66.3M | $37.4M |
| Pre-Tax Income | $177.9M | $170.6M | $108.6M | $102.5M | $76.4M | $41.5M |
| Income Tax | $53.3M | $54.1M | $39.3M | $38.7M | $34.3M | $30.1M |
| Net Income | $124.7M | $116.5M | $69.3M | $63.8M | $42.0M | $10.8M |
| Diluted EPS | $5.86 | $5.73 | $3.59 | $3.30 | $2.19 | $0.58 |
Usana Health Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $213.7M | $226.2M | $250.2M | $223.3M |
| Net Income | -$6.5M | -$1.8M | $7.5M | -$21.4M |
| Diluted EPS | -$0.36 | -$0.10 | $0.41 | -$1.16 |
Usana Health Sciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $311.9M | $239.8M | $288.4M | $330.4M | $181.8M | $158.4M |
| Current Assets | $425.3M | $365.1M | $384.4M | $417.7M | $279.2M | $288.4M |
| Total Assets | $640.9M | $577.7M | $596.5M | $632.8M | $748.2M | $742.9M |
| Current Liabilities | $168.1M | $160.8M | $143.8M | $118.8M | $139.6M | $128.6M |
| Total Liabilities | $199.2M | $182.6M | $162.1M | $135.6M | $161.9M | $156.6M |
| Shareholders' Equity | $441.6M | $395.1M | $434.5M | $497.2M | $532.1M | $533.1M |
Usana Health Sciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $160.4M | $121.2M | $103.9M | $70.6M | $61.0M | $22.3M |
| Cash From Investing | -$34.0M | -$14.2M | -$12.4M | -$12.0M | -$213.1M | -$10.1M |
| Cash From Financing | -$59.4M | -$181.4M | -$30.1M | -$14.2M | $9.6M | -$40.6M |
| Free Cash Flow | $145.3M | $108.5M | $93.5M | $56.1M | $50.9M | $8.5M |
Figures from Usana Health Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Usana Health Sciences financials page for every line item.
Usana Health Sciences Company Profile
| Ticker | USNA |
|---|---|
| Exchange | NYSE |
| Industry | Medicinal Chemicals & Botanical Products |
| Headquarters | Salt Lake City, Utah |
| Incorporated in | Utah |
| Fiscal Year End | January 3 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0000896264 |
Frequently Asked Questions
What was Usana Health Sciences' revenue in fiscal 2025?
Usana Health Sciences (USNA) reported revenue of $925.3M for fiscal 2025.
What is Usana Health Sciences' annual revenue history?
Usana Health Sciences' annual revenue by fiscal year: 2020: $1.13B; 2021: $1.19B; 2022: $998.6M; 2023: $921.0M; 2024: $854.5M; 2025: $925.3M.
What was Usana Health Sciences' net income in fiscal 2025?
Usana Health Sciences reported net income of $10.8M for fiscal 2025.
What was Usana Health Sciences' earnings per share (EPS) in fiscal 2025?
Usana Health Sciences' diluted EPS was $0.58 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Usana Health Sciences generate in fiscal 2025?
Usana Health Sciences generated $8.5M of free cash flow in fiscal 2025.
What was Usana Health Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Usana Health Sciences reported revenue of $223.3M.
How many shares of Usana Health Sciences are outstanding?
Usana Health Sciences reported a weighted average of 18.5 million basic shares outstanding in 2026 Q2.
What is Usana Health Sciences' market cap?
Based on its latest closing price, Usana Health Sciences (USNA) has a market capitalization of about $285.8M.
When does Usana Health Sciences' fiscal year end?
Usana Health Sciences' fiscal year end, as registered with the SEC, is January 3.
Where is Usana Health Sciences headquartered?
Usana Health Sciences lists its business address in Salt Lake City, Utah in its SEC filings.
Usana Health Sciences Competitors & Similar Companies
See all 11 Medicinal Chemicals & Botanical Products companies →